XOLREMDI
Growthmavorixafor
NDAORALCAPSULEPriority Review
Approved
Apr 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
7
Data completeness
4/8 — Partial
Priority Review
XOLREMDI (mavorixafor) is cxc chemokine receptor 4 antagonists [moa]. First approved in 2024.
Drug data last refreshed 2d ago
Mechanism of Action
CXC Chemokine Receptor 4 Antagonists
Pharmacologic Class:
CXC Chemokine Receptor 4 Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (7)
A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function
Started Feb 2025
48 enrolled
Hepatic Insufficiency
Drug-Drug Interaction Potential of Mavorixafor
Started Feb 2025
38 enrolled
Healthy Participants
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
Started Jun 2024
176 enrolled
Neutropenia
A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders
Started Oct 2021
32 enrolled
Neutropenia
A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4
Started Apr 2020
16 enrolled
Waldenstrom's Macroglobulinemia
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.